Lymphoma

P1, N=10, Active, not recruiting, Baylor College of Medicine | Trial completion date: Jul 2026 --> Jul 2027

P2, N=25, Not yet recruiting, Jennifer Woyach | Initiation date: May 2026 --> Sep 2026

P1, N=46, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2030 --> May 2028 | Trial primary completion date: Feb 2030 --> May 2028

The final diagnosis was CD20-negative primary intestinal large B-cell lymphoma with a TP53 mutation arising in the context of poorly controlled CD, a combination that, to the best of our knowledge, has not been previously reported in the literature. This case highlights the diagnostic challenges posed by intestinal lymphomas associated with CD and emphasizes the importance of integrating histopathological, immunophenotypic, and molecular findings to achieve an accurate diagnosis and provide prognostic assessment.

DCA revealed that this fusion model offers a significant clinical net benefit for prognostic risk prediction in DLBCL patients over a wide threshold probability range of 0.05-0.900. The fusion model, combining PET/CT deep features with clinical characteristics, is a dependable prognostic tool for DLBCL, holding substantial promise for clinical application and personalized treatment.

The 5‑index risk model demonstrated robust predictive ability in a real‑world setting, providing a reliable basis for personalized treatment decisions in Chinese DLBCL patients undergoing CAR‑T. Future work will focus on further optimizing the model and conducting multi‑regional validation.

Following multidisciplinary consultation, the patient was treated with the bendamustine plus rituximab (BR) regimen. Second, for WM patients with renal AL amyloidosis, choosing BR regimen as the first-line treatment is reasonable. However, during the treatment process, it is essential to closely monitor and actively prevent the adverse effects of this regimen, particularly severe infections which may have fatal consequences.

Histological analysis revealed milder dysplasia in the cocoa-treated group compared to controls (p=0.002). Cocoa extract demonstrates potential as a natural chemopreventive agent against skin cancer through antioxidant activity, anti-angiogenesis, and apoptosis modulation pathways.

Patient-derived transcriptomes exhibited enrichment of pathways that were functionally related to the gene signatures observed in the xenograft model. These findings suggest that CNS-preferential dissemination in DLBCL is associated with coordinated signaling involving PI3K/ARF6 activation and suppression of S1P-mediated pathways, providing molecular insights with potential implications for risk stratification and therapeutic targeting in sCNSi.

P1, N=48, Recruiting, Sawa Ito, MD | Not yet recruiting --> Recruiting

P1, N=14, Recruiting, Abramson Cancer Center at Penn Medicine | Not yet recruiting --> Recruiting

P=N/A, N=180, Recruiting, University of Nebraska | Phase classification: P2 --> P=N/A